Abstract
Following the result of Checkmate 743, dual checkpoint inhibition is a standard of care for unresectable malignant pleural mesothelioma (MPM). There is an ongoing need for potential predictive biomarkers for both efficacy and toxicity. To determine how the tumour microenvironment impacts ICI treatment outcomes and irAEs, we have designed a pilot study to determine the role of tumour-infiltrating immune cells on Ipilimumab (IPI) + Nivolumab (NIVO) treatment.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
